C. Difficile

July 2nd 2025

A multicenter US study confirms that RBL is a safe and effective microbiota-based therapy with sustained remission in a high-risk, comorbid population.

June 30th 2025

Use of an AI-guided infection prevention bundle did not significantly reduce CDI incidence but was associated with increased antimicrobial stewardship.

June 20th 2025

At ASM Microbe 2025, researchers underscored the role of NAAT in outpatient CDI diagnosis and raised concerns over PPI-related risk in older, health care–associated cases.

June 19th 2025

A study presented at ASM Microbe 2025 questions the clinical value of adding enzyme immunoassays to PCR-based CDI diagnostics amid sensitivity concerns.